Oramed Pharmaceuticals (NASDAQ:ORMP) Share Price Passes Above Fifty Day Moving Average - Should You Sell?

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Get Free Report)'s share price crossed above its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $2.22 and traded as high as $2.25. Oramed Pharmaceuticals shares last traded at $2.11, with a volume of 141,792 shares changing hands.

Analysts Set New Price Targets

Separately, Wall Street Zen downgraded shares of Oramed Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday, May 17th.

Oramed Pharmaceuticals Trading Down 0.9%

The firm has a market cap of $86.19 million, a price-to-earnings ratio of -4.80 and a beta of 1.63. The stock's 50 day moving average is $2.22 and its 200 day moving average is $2.28.

Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) last issued its quarterly earnings data on Thursday, May 15th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.03) by ($0.16). The firm had revenue of $2.00 million during the quarter. On average, equities research analysts predict that Oramed Pharmaceuticals Inc. will post -0.03 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in ORMP. Dimensional Fund Advisors LP increased its holdings in shares of Oramed Pharmaceuticals by 143.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 118,995 shares of the biotechnology company's stock worth $288,000 after purchasing an additional 70,190 shares during the period. Boothbay Fund Management LLC grew its position in Oramed Pharmaceuticals by 2.0% during the fourth quarter. Boothbay Fund Management LLC now owns 845,188 shares of the biotechnology company's stock worth $2,045,000 after buying an additional 16,857 shares in the last quarter. BML Capital Management LLC increased its stake in Oramed Pharmaceuticals by 20.9% during the 4th quarter. BML Capital Management LLC now owns 2,643,907 shares of the biotechnology company's stock worth $6,398,000 after acquiring an additional 457,716 shares during the period. World Equity Group Inc. acquired a new position in Oramed Pharmaceuticals in the 4th quarter valued at $48,000. Finally, Jane Street Group LLC lifted its position in shares of Oramed Pharmaceuticals by 35.3% during the 1st quarter. Jane Street Group LLC now owns 67,173 shares of the biotechnology company's stock valued at $144,000 after acquiring an additional 17,510 shares during the period. Institutional investors own 12.73% of the company's stock.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.